Navigation Links
Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results
Date:5/9/2011

financial measures, management intends to provide investors with a meaningful, consistent comparison of the company's core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.(c) This table includes Adjusted Non-GAAP (Cash) Earnings Per Share, which is a non-GAAP financial measure that represents earnings per share, excluding amortization of inventory step-up, amortization of alliance product assets & pp&e step up, stock-based compensation step-up, restructuring and acquisition-related costs, acquired in-process research and development ("IPR&D"), legal settlements outside the ordinary course of business, amortization and other non-cash charges, amortization of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest, loss on extinguishment of debt, (gain) loss on investments, net, and adjusts tax expense to cash taxes. (d) ASC 805, accounting for business combinations requires an inventory fair value step-up. The impact of the amortization of this step-up is included in cost of goods sold. For the three months ended March 31, 2011 the total impact is $29.9 million. A total of  $26.4 million for the merger with Valeant Pharmaceutical International, and $3.5 million pertaining to the acquisition of Pharma Swiss SA on March 10, 2011.(e) Alliance product assets & pp&e step-up represents the step up to fair market value from Legacy Valeant's original cost resulting from the merger of Legacy Valeant into Legacy Biovail. The impact of the amortization of this step-up is included in cost of alliance and royalty & SG&A. For the three months ended March 31, 2011 the total impact is $19.1 million. (f) Total stoc
'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Valeant Announces Pricing of Senior Notes
9. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
10. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
11. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)... Jan. 15, 2014  In an unprecedented effort to curb the spread ... and other transport vehicles, an advanced and portable UV germicidal lamp ... the first time. In order to prevent EMS ... pathogens, West Palm Beach Fire Rescue is ...
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Pa., Oct. 29 Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today ... Credit Suisse Healthcare Conference to be held November 10-12, 2010 ... Fickenscher, Chief Financial Officer, is scheduled to present an overview ... ET on Thursday, November 11, 2010. To listen ...
... Calif., Oct. 28 VIVUS, Inc. (Nasdaq: ... Response Letter (CRL) from the U.S. Food and Drug ... the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The ... the NDA cannot be approved in its present form. ...
Cached Medicine Technology:Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference 2Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference 3FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 2FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 3FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 4FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 5
(Date:4/18/2014)... This news release is available in French . ... breakthrough could revolutionize surgical practice and regenerative medicine. A ... Molle et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur ... and Paris 13), has just demonstrated that the principle ... used in vivo to repair soft-tissue organs and tissues. ...
(Date:4/17/2014)... identified new pain relief targets that could be ... researchers at King,s College London made the discovery ... the periphery of the body. , Dr Marzia ... mechanisms underlying pain generation and our findings could ... effects." , One potential side effect of some ...
(Date:4/17/2014)... AURORA, Colo. (April 17, 2014) Two recent ... Medicine researcher and colleagues may help scientists develop ... virus, Yellow fever, Japanese encephalitis and other disease-causing ... of biochemistry and molecular genetics at the School ... the Howard Hughes Medical Institute, and colleagues recently ...
(Date:4/17/2014)... who treat patients with a severe and progressive ... agonizing treatment decision. , The drug sirolimus can ... shortness of breath. But some patients eventually may ... fatal complications following transplantation. , "It,s a terrible ... of Loyola University Medical Center,s LAM Clinic and ...
(Date:4/17/2014)... School of Medicine (BUSM) have discovered that the ... experimental model. The findings, reported in the ... may lead to more effective treatments for alcoholism. ... the leading causes of illness and death in ... by limiting the productivity of workers and necessitating ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... phone use on the road: studies , MONDAY, Sept. 28 ... difference in your teen,s safety once he or she gets ... firm rules, but do so in a helpful, supportive way, ... auto accident by half and decrease rates of drinking and ...
... 2009 Researchers at UT Southwestern Medical Center ... and lung cancer have become more prevalent among ... of anti-retroviral therapies in the mid-1990s. ... higher risk for so-called AIDS-defining malignancies cancers ...
... are invited to attend a gathering of the nation,s leading ... and develop programs that may help lower the nation,s costly ... held Oct. 8 and 9 in Arlington, Virginia, is a ... of Obstetricians and Gynecologists, the American Academy of Pediatrics, American ...
... approach to understanding how cells develop resistance to drugs has ... Anderson Cancer Center a New Innovator Award from the National ... M. D. Anderson,s Department of Systems Biology, will receive $1.5 ... NIH announced awards Thursday in three prestigious programs that fund ...
... Warning follows report that dosing instructions for liquid medication ... News) -- U.S. health officials have issued a public ... errors involving liquid Tamiflu for kids. , The alert, ... parents could give the wrong dose of Tamiflu to ...
... ... recognized in 42 states, gives consumers control over healthcare costs, saving time and money ... Philadelphia, ... out-patient physical therapy clinic with eight locations throughout the Philadelphia region, indicate that awareness ...
Cached Medicine News:Health News:Firm Parents Keep Teen Drivers Safe 2Health News:Firm Parents Keep Teen Drivers Safe 3Health News:Certain cancers more common among HIV patients than non-HIV patients 2Health News:Experts to review quality improvement programs to prevent preterm birth 2Health News:Experts to review quality improvement programs to prevent preterm birth 3Health News:M. D. Anderson scientist wins NIH New Innovator Award 2Health News:M. D. Anderson scientist wins NIH New Innovator Award 3Health News:FDA Issues Health Alert on Kids' Tamiflu Dosages 2Health News:FDA Issues Health Alert on Kids' Tamiflu Dosages 3Health News:According to Excel Physical Therapy and Fitness, Awareness Still Low for Law that Allows People to go Directly to a Physical Therapist without a Doctor's Prescription 2Health News:According to Excel Physical Therapy and Fitness, Awareness Still Low for Law that Allows People to go Directly to a Physical Therapist without a Doctor's Prescription 3
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: